First approved in 2006 as an asthma treatment, AstraZeneca’s (LON:AZN) Symbicort (budesonide/formoterol) has also won an indication related to chronic obstructive pulmonary disease (COPD). Now, FDA has approved the first generic of Symbicort for both indications. Viatris (Nasdaq:VTRS) partnered with Kindeva Drug Delivery (St. Paul, Minnesota) to manufacture the generic version. Last week, the companies…

Viatris (NASDAQ: VTRS) shares skidded 24% yesterday to $11.01 after announcing it would sell its biosimilars portfolio to Biocon Biologics for as much as $3.335 billion. The former company unveiled the news when announcing its fourth-quarter earnings. Viatris will pay $2 billion upfront, $1 billion in convertible preferred equity, and $335 million in additional payments…

Pfizer (NYSE:PFE) agreed to pay $345 million to settle claims of overpayments for EpiPens due to alleged anti-competitive and unfair practices. Reuters reported that a filing disclosed in federal court in Kansas City, Kan., revealed the settlement set to resolve claims from consumers who say they overpaid for EpiPens with the alleged anti-competitive and unfair practices by…

Pfizer (NYSE:PFE) expects common stock for its Viatris spin-off to be available starting Nov. 12, following the U.S. Federal Trade Commission’s approval of the proposed merger of Mylan (NSDQ:MYL) and Pfizer’s biopharmaceutical Upjohn brand.  The company expects the “when-issued” market for Viatris common stock (VTRSV) to be available from Nov. 12 to Nov. 16, when it…

Mylan (NSDQ:MYL) and Pfizer (NYSE:PFE) recently announced that the U.S. Federal Trade Commission had signed off on the proposed merger of Mylan and Pfizer’s biopharmaceutical-focused Upjohn brand. Upjohn also includes Pfizer’s Greenstone generic-drug unit. It also owns the rights to Lipitor and Xanax. Pfizer plans to spin out Upjohn on Nov. 13. If all goes…